Genflow’s update on its canine aging program — an early progress report examining safety signals and biological-age measures that hints at how dog studies might speed translational longevity research.
Key Takeaways
- Genflow reported improved three-month survival in treated older beagles compared with control groups
- No adverse events were observed in the treated dogs during the initial three-month follow-up
- Company is analyzing biological age markers and muscle health, with six-month data expected next